

# Poster Presentation on AS-1763 at 2022 AACR Annual Meeting



On April 11, 2022, Carna Biosciences presented two posters highlighting the drug discovery and the result of the SAD part of Phase 1 study for AS-1763, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner, at the American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans, Louisiana.

